Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within days prior to registration Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within days prior to Day . Negative pregnancy test (urine or serum beta human chorionic gonadotropin [b-hCG]) at Screening for women of child bearing potential who are sexually active Negative urine ?-human chorionic gonadotropin (?-HCG) pregnancy test for fertile women at screening and confirmed by serum pregnancy test in the hours prior to OPN- administration Serum creatinine ?. mg/dL or a measured creatinine clearance ? mL/min; and Negative serum ? hCG (human chorionic gonadotropin) test in women of childbearing potential (defined as women ? years of age, or > years of age with a history of amenorrhea for ? months prior to study entry). Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for days following the last dose of study drug; females of non-childbearing potential are those who are post-menopausal for more than year or who have had a bilateral tubal ligation or hysterectomy Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial; pregnant women are excluded from this study; breastfeeding is not allowed during the course of the study; female patients must have a negative pregnancy test (human chorionic gonadotropin beta subunit [B-HCG] test in urine or serum) prior to commencing study treatment Have a negative beta-human chorionic gonadotropin (?-hCG) pregnancy test at time of study entry and within days prior to planned first dose of investigational product, and Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study Female of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test result within days of first study dose; female patients who are surgically sterilized or who are > years old and have not experienced menses for > years may have beta-HCG pregnancy test waived Patients who are women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented =< days prior to registration Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening PART I: Negative serum beta human chorionic gonadotropin (HCG) if female and of childbearing potential PART II: Negative serum beta HCG if of childbearing potential Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Pregnancy (absence to be confirmed by beta-human chorionic gonadotropin test in women of child-bearing potential) or lactation Negative serum beta-human chorionic gonadotropin (HCG) in females, and agreement to the use of effective contraception in males and females of childbearing potential, IS REQUIRED Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to registration Positive urine pregnancy test (women of child bearing potential only) (QuickVue One Step human chorionic gonadotropin [hCG]) Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin or urine pregnancy test at screening Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening, within hours of the first dose of anti-OX antibody, and every four weeks while on study treatment; women who are pregnant or breastfeeding are ineligible for this study Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (Beta human chorionic gonadotropin [beta-hCG]) or urine Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) within weeks of protocol entry if the patient is unsure of their pregnancy status. Patient signature declaring that they are not pregnant on the informed consent for treatment that is used in the Department of Radiation Oncology is also an acceptable substitution for a serum pregnancy test. A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum) Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy. Negative serum beta-human chorionic gonadotropin (hCG) pregnancy test within hours of day of induction chemotherapy in women of child-bearing potential Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than months after menopause Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than months after menopause; [women are considered postmenopausal if they are >= months without menses, in the absence of endocrine or anti-endocrine therapies] Female patients of childbearing potential must have a negative serum beta?human chorionic gonadotrophin (?-hCG) pregnancy test at screening and negative urine pregnancy test at Cycle Day prior to the first dose of study drug. Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening and within days prior to planned first dose of ribociclib Female subjects of childbearing potential should have a negative urine or serum pregnancy test beta human chorionic gonadotropin (beta-hCG) within hours prior to receiving the first dose of study medication Negative beta-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential =< days before starting neratinib therapy Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study Negative urine or serum beta-human chorionic gonadotropin (BHCG) for women of childbearing potential only (within days of registration) For patients of childbearing potential, non-pregnant state, confirmed by negative serum or urine beta-human chorionic gonadotropin (HCG) within () days of planned radiation treatment Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study Negative beta-human chorionic gonadotropin (hCG) pregnancy test within weeks before enrollment for premenopausal women of reproductive capacity and for women less than months after menopause; pregnancy screening will be conducted for women up to the age of years per institutional standard Negative urine beta-human chorionic gonadotropin (B-HCG) in women of child-bearing potential within days prior to start of treatment Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within hours prior to the first dose of treatment and must agree to use an effective contraception method to avoid pregnancy for weeks ( days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drugs; females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within hours of study start) Negative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of childbearing potential only), to be performed locally within the screening period Negative serum or urine beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential* only), to be performed locally within the screening period Women of child-bearing potential (WOCBP) must have a negative pregnancy test within days of the first administration of study treatment; urine human chorionic gonadotropin (HCG) is an acceptable pregnancy assessment Female patients of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) within weeks of protocol entry Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of mobilization Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for female patients of childbearing potential All post-menarchal females must have a negative serum beta-human chorionic gonadotropin (beta HCG); sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least months after Patients may not be pregnant or breast feeding; females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within days prior to the first dose of S-equol Negative serum or urine pregnancy test beta-human chorionic gonadotropin (beta hCG) within weeks prior to receiving the first dose of study medication for women of childbearing age Negative pregnancy test (beta [B]-human chorionic gonadotropin [HCG]) within days prior to registration for women of childbearing potential Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential within one week prior to enrollment Negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study Women of childbearing potential must have a negative beta (B)-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to registration Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) (to be performed within days prior to start of study treatment) Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [BhCG]) within weeks of protocol entry Females of childbearing potential (> years old [yo]) must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test prior to initiation of cytoreductive therapy; sexually active patients will be informed of the risk of not using adequate contraception Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to treatment Negative serum or urine beta-human chorionic gonadotropin (b-hCG) pregnancy test at screening for patients of childbearing potential DONOR: Not be pregnant as defined by negative serum (beta human chorionic gonadotropin [beta HCG]) pregnancy test in females of childbearing potential (non-childbearing potential defined as premenarchal, previous surgical sterilization, or postmenopausal for > months) Women of childbearing age must have a negative serum pregnancy test (beta-human chorionic gonadotropin) within hours prior to initiating the conditioning regimen and be willing to not become pregnant by using effective contraception while undergoing treatment and for at least months after the last dose of azacitidine DLI DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within week of beginning apheresis Female patients of childbearing age will be excluded if they are pregnant as assessed by serum beta-human chorionic gonadotropin (b-HCG) or urine pregnancy test; a serum b-HCG test or urine pregnancy test will be performed no greater than days prior to study registration Female patient of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (hCG) within hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [B HCG]) within hours of receiving the first dose of rituximab Women of childbearing potential must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within days prior to taking the first dose of study medications Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (?-human chorionic gonadotropin) within days prior to randomization. For female patients of childbearing potential (i.e. have had a menstrual period within the past months): a positive serum pregnancy test (?-human chorionic gonadotropin) within days prior to enrollment. and, have a negative serum pregnancy test at Screening, (Note: Subjects with elevated serum beta human chorionic gonadotropin (?hCG) and a demonstrated non-pregnant status through additional testing are eligible), and A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at Screening and a negative urine pregnancy test prior to the first dose of study drug Negative serum pregnancy test (serum HCG) within days of study treatment if female and of childbearing potential (non-childbearing is defined as greater than one year post-menopausal surgically sterilized). Since beta-HCG may be falsely elevated as a result of malignancy, women of child-bearing potential who have an elevated serum beta-HCG level are eligible for enrollment if they have two Transvaginal Ultrasound (TVUS) scans one week apart along with serial beta-HCG levels two weeks apart that are inconsistent with pregnancy and a Gynecology consult to ensure that the beta- HCG level was at a value high enough to see pregnancy with TVUS. Not pregnant based on a negative result on a serum human chorionic gonadotropin (HCG) test at screening Visit and a negative urine pregnancy test prevaccination at Visit (and at subsequent vaccination visits); Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within hours (hrs) prior to first dose Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (B-hCG) pregnancy test result within days prior to the first dose of imipramine Negative serum or urine beta-human chorionic gonadotropin (HcG) test (female patient of childbearing potential only) performed within hours of prior to first study dose Pregnancy test (urine or serum beta-human chorionic gonadotropin [HCG]) done within hours before randomization must be negative (for women of childbearing potential only); if urine pregnancy results are positive or cannot be confirmed as negative, a serum pregnancy test will be required A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin [b-hCG]) or urine test prior to the first dose of study drug DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within two weeks of apheresis Women of childbearing potential must have a negative serum ?-human chorionic gonadotropin or urine pregnancy test at screening DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotrophin (HCG) test within three weeks of mobilization Pregnancy during vaccine administration; female participants of childbearing potential must have a negative pregnancy test (serum beta human chorionic gonadotropin [B-HCG]) prior to administration of the first vaccine dose Women who are pregnant or breastfeeding; women of child-bearing potential must have a negative pregnancy test (beta- human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only) Women of childbearing potential must have a negative serum beta (B)-human chorionic gonadotropin (HCG) pregnancy test at initial screening and within days prior to registration Female patients of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (hCG) Woman of childbearing potential must have negative highly sensitive serum (beta-human chorionic gonadotropin [b-hCG]) during screening, the first one within to days prior to the first dose of any component of study treatment and the second within hours prior to the first dose of any component of study treatment Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Females of childbearing potential must have a negative beta human chorionic gonadotropin (?-hCG) pregnancy test result within days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy. Women of childbearing potential must have a negative urine or serum beta-human chorionic gonadotropin pregnancy test within days prior to Day . Female participants of childbearing potential must have negative urine human chorionic gonadotropin tests within to days and within hours prior to receiving study medication Negative blood or urine beta-human chorionic gonadotropin (?- HCG) pregnancy test within days prior to Day for women of childbearing potential. Female participants of reproductive potential must not be pregnant (negative urine or serum human chorionic gonadotropin test within hours of study start) Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within days prior to the first dose of ibrutinib; females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy Negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening for patients of childbearing potential Negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening for patients with childbearing potential Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test result within days prior to the first dose of SGN-; females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy Negative serum pregnancy test (beta human chorionic gonadotropin [beta HCG]) within days of starting study, if of child-bearing potential A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta- hCG]) at Screening within days prior to study drug administration Inclusion Criteria for Crossover: Pregnancy or breast feeding; female patients must have a negative pregnancy test (beta-human chorionic gonadotropin [HCG] test in urine or serum) prior to commencing study treatment and must agree with the use of effective contraception during the study and for three months following last dose of nintedanib Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test within hours of study start) Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [Beta-hCG]) pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study; females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program Negative pregnancy test (serum beta-human chorionic gonadotropin [B-HCG]) within days of starting study treatment is required in women of childbearing potential; NET patients with positive B-HCG are eligible if pregnancy can be excluded by vaginal ultrasound or lack of expected doubling of B-HCG Negative serum pregnancy test (beta-human chorionic gonadotropin [B-hCG]) within hours before starting study treatment for all women of childbearing potential Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to treatment DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within week of beginning growth factor of choice Negative urine beta-human chorionic gonadotropin (HCG) or negative serum quantitative beta-HCG or within weeks prior to registration for women of childbearing potential Negative serum human chorionic gonadotrophin (HCG) pregnancy test for premenopausal women of reproductive capacity and for women less than months after menopause Negative beta-human chorionic gonadotropin (hCG) pregnancy test for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than months after menopause Women of childbearing potential (including premenopausal women and women less than months after menopause) must have a negative beta-human chorionic gonadotropin (hCG) urine pregnancy test within weeks of registration Premenopausal women of child bearing potential must have a normal urine or serum beta-human chorionic gonadotropin (HCG) prior to enrollment, and must agree to use effective contraception during treatment with nivolumab and for at least months following the last dose of nivolumab Women of childbearing potential must have a negative pregnancy test (serum or urine beta human chorionic gonadotropin [HCG]) prior to initiation of chemotherapy; both female and male breast cancer patients who are sexually active have to agree to practice contraception while participating in the trial and for month after completion of therapy Patients will be excluded if they are pregnant as assessed by serum beta human chorionic gonadotropin (b-HCG); a serum b-HCG test will be performed no greater than days prior to study registration for women of childbearing potential Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Females of child-bearing potential (pre-menopausal) must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test at screening Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within hours of day of induction chemotherapy in women of child-bearing potential Negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test within hours of day of treatment with ABVD in women of child-bearing potential Urine or serum beta-human chorionic gonadotropin (HCG) or serum HCG = negative (if female patient of childbearing potential) Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within hours of start of therapy Female patient of childbearing potential must have a negative serum or urine pregnancy test (beta-human chorionic gonadotropin [hCG]) within hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study Female patient of childbearing potential has a negative serum pregnancy test beta-human chorionic gonadotropin (b-hCG) within days prior to receiving the first dose of vorinostat Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test beta-human chorionic gonadotropin (hCG) within days of the first treatment Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery) Negative serum beta human chorionic gonadotropin (?hCG) test (for women of childbearing potential only) Patients of childbearing potential must agree to use some form of adequate birth control during the periods they receive chemotherapy and any post-chemotherapy medications related to the transplant; females of child bearing potential must have a negative serum beta-human chorionic gonadotropin (B-HCG) within week of starting therapy DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within week of beginning G-CSF mobilization Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test at screening and again within hours prior to receiving the first dose of study therapy) Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) or urine pregnancy test at screening Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) pregnancy test at screening; pregnancy testing is not required for: (a) women who have been post-menopausal for at least years without menses; or (b) women who are surgically sterile (e.g. by means of hysterectomy, tubal ligation, etc.) Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening within days of enrollment Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within hours of study start) Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only), to be performed locally within the screening period Negative beta human chorionic gonadotropin (bHCG) within days prior to study entry if patient is pre or perimenopausal Negative pregnancy test (beta human chorionic gonadotropin [HCG]) within days of study drug initiation for pre- or perimenopausal subjects with an intact uterus Negative serum beta-human chorionic gonadotropin (B-HCG) test (female patient of childbearing potential only) performed locally within hrs prior to first dose If a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [hCG]) documented within hours of the first administration of study drug Male or non-pregnant and non-lactating female; if a female patient is of childbearing potential, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin [b-hCG]) documented within hours of the first administration of study drug Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening for patients of childbearing potential A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(-hCG) as verified by the study doctor within hours prior to starting study therapy. Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test within days of day (D) of neoadjuvant chemotherapy for women of childbearing potential If female patient is of child bearing potential, she must have a negative serum pregnancy test (beta human chorionic gonadotropin [hCG]) documented up to hours (hrs) prior to administration of first study drug Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within days prior to the first dose of brentuximab vedotin and must agree to use an effective contraception method during the study and for days following the last dose of study drug; females of non-childbearing potential are those who are postmenopausal greater than year or who have had a bilateral tubal ligation or hysterectomy Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) performed locally within hours (hrs) prior to first dose Negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening, performed no more than hours prior to treatment initiation; for women of childbearing potential A positive urine and/or serum beta-human Chorionic Gonadotropin pregnancy test Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to registration Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within hours prior to receiving the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin beta subunit [B-hCG] pregnancy test) within hours prior to receiving the first dose of vorinostat; male patients enrolled in this study should also agree to use an adequate method of contraception for the duration of the study DONOR: Females of childbearing potential should have a negative serum beta-human chorionic gonadotropin (HCG) test within week of beginning apheresis Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) Negative beta human chorionic gonadotropin (HCG) in woman with child-bearing potential Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test within days prior to treatment initiation and when clinically indicated every weeks +/- days while receiving study drugs, as shown in study calendar; women who are pregnant or breastfeeding are ineligible for this study Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Within weeks of therapy start, women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening and must adhere to the scheduled pregnancy testing Negative serum beta (?) human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within hours prior to first dose Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within days prior to registration Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening; women who are pregnant or breastfeeding are ineligible for this study A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum beta-human chorionic gonadotrophin [beta-hCG] test) in females of reproductive potential), not lactating or if of reproductive potential agrees to follow one of the options listed in protocol from days prior to the first dose of study medication and until days after the last dose of study treatment. Negative beta-human chorionic gonadotropin (betaHCG) pregnancy test among females of childbearing age Pregnancy or breast feeding; female patients with child-bearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [B-HCG] test in urine or serum) prior to commencing study treatment If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study\r\n* Women < years old must have a negative pregnancy test (urine human chorionic gonadotropin [HCG] or serum betaHCG) within weeks of beginning chemotherapy Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration DONOR: Female donors of child-bearing potential must have a negative serum or urine beta-human chorionic gonadotropin (HCG) test within three weeks of apheresis Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential Women of childbearing age will be required to have a negative human chorionic gonadotropic (HCG) test within seven days of surgery Minocycline trial only: patients who are pregnant; pregnancy will be confirmed by negative urine test; patients with a positive urine test will be retested for doubling of human chorionic gonadotropin (HCG) hours after the first test; patients without such a rise will be eligible for the study and will be enrolled at the investigators discretion Female subjects capable of reproduction must have a negative beta human chorionic gonadotropin (BHCG) serum or urine pregnancy test result within days prior to first Investigational Product dose Negative pregnancy test (females of child bearing potential) within =< week of rasburicase dose and use of efficient contraceptive method (both males and females); pregnancy test may be performed on serum (human chorionic gonadotropin [HCG]) or urine (HCG) RECIPIENT: Negative serum or urine beta?human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration Women of child-bearing potential must also have a negative urine pregnancy test (beta-human chorionic gonadotropin [HCG]) within hours of receiving treatment Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of childbearing potential only) Women of childbearing potential, unless they have had a negative urine beta human chorionic gonadotropin (betaHCG) within the previous hours of the procedure All post-menarchal females must have a negative beta-human chorionic gonadotropin (HCG) within weeks prior to receiving the dose of I-MIBG; males and females of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus Women of childbearing potential, unless they have had a negative urine human chorionic gonadotropin (HCG) within the previous hours of the procedure Negative serum ? -HCG (beta human chorionic gonadotropin) test for female of child bearing potential at screening and a negative urine pregnancy test at Day . Subjects who are pregnant or nursing; urine pregnancy test/or serum human chorionic gonadotropin (HCG) will be performed on women of child bearing potential Women of childbearing potential must have a negative beta-human chorionic gonadotropin pregnancy test documented within days prior to treatment. Have given written informed consent prior to any study-specific procedures. Negative urine or serum beta-human chorionic gonadotropin (?-HCG) pregnancy test within days prior to the Cycle , Day visit, for women of childbearing potential.